With approval from the European Commission secured in September for the combination of its BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib), Pierre Fabre Group is now focusing on access for its metastatic melanoma therapy in a crowded market.
The combo got the green light in Europe last month based on data from the Phase III COLUMBUS trial in...






